B
Belite Bio, Inc (BLTE)
NCM – Real Time Price. Currency in USD
148.73
-1.10 (-0.73%)
At close: Jun 26, 2026, 4:00 PM EDT
149.00
+0.27 (0.18%)
After-hours: Jun 26, 2026, 6:07 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
148.73
-1.10 (-0.73%)
At close: Jun 26, 2026, 4:00 PM EDT
149.00
+0.27 (0.18%)
After-hours: Jun 26, 2026, 6:07 PM EDT
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-06-15 | 6-K | tm2617120d1_6k.htm |
| 2026-05-20 | 6-K | tm2614933d1_6k.htm |
| 2026-04-21 | 6-K | tm2611999d1_6k.htm |
| 2026-03-31 | 6-K | tm261133d2_6k.htm |
| 2026-03-31 | 20-F | blte-20251231x20f.htm |
| 2026-03-02 | 6-K | tm267429d1_6k.htm |
| 2026-01-30 | S-8 | tm264429d1_s8.htm |
| 2026-01-27 | 6-K | tm264022d1_6k.htm |
| 2025-12-02 | 6-K | tm2532416d4_6k.htm |
| 2025-12-01 | 6-K | tm2532416d1_6k.htm |